In this Review, Pantel and Alix-Panabières provide an overview of approaches for the detection and characterization of minimal residual disease (MRD) using circulating tumour cells and circulating tumour DNA. They also discuss the clinical implications of such liquid biopsy approaches to MRD monitoring for the management of patients with cancer.
Nature Reviews Clinical Oncology – The development of clinically relevant artificial intelligence (AI) models has traditionally required access to extensive labelled datasets, which inevitably…
Nature Reviews Clinical Oncology – Although ovarian cancer is considered an immunoreactive disease, moderate to no efficacy has been shown in the trials testing immune-checkpoint…
Nature Reviews Clinical Oncology – Endometrial cancer is the commonest gynaecological cancer in economically developed countries, and both the incidence and mortality continue to increase.…
Nature Reviews Clinical Oncology – Endometrial cancer is the commonest gynaecological cancer in economically developed countries, and both the incidence and mortality continue to increase.…
Nature Reviews Clinical Oncology – Patients with advanced-stage hormone receptor-positive (HR+) breast cancer typically receive first-line treatment with anti-oestrogen-based agents, often combined…
On August 19, 2024, the FDA approved lazertinib (Lazcluze, Janssen Biotech, Inc.) with amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) for NSCLC.
Nature Reviews Clinical Oncology – Several different viruses have a role in cancer pathogenesis, contributing to the development of various haematological malignancies and solid tumours…
On August 15, 2024, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) for resectable non-small cell lung cancer.
Nature Reviews Clinical Oncology – Blinatumomab improves outcomes in adult MRD-negative BCP-ALL
On August 6, 2024, the Food and Drug Administration approved vorasidenib (Voranigo, Servier Pharmaceuticals LLC). Learn more.
